Medistim ASA (FRA:MD1) Cyclically Adjusted Revenue per Share: €2.46 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MD1 Medistim ASA FRA:MD1
99 GF Score
Price €20.20
GF Value €23.18
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Medistim ASA Cyclically Adjusted Revenue per Share?

Medistim ASA FRA:MD1 -0.98% 99 Cyclically Adjusted Revenue per Share is €2.46 as of Mar. 2026. GuruFocus rates FRA:MD1 with a GF Score™ of 99/100 and a GF Value™ of €23.18 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Medistim ASA's adjusted revenue per share for the three months ended in Mar. 2026 was €0.988. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.46 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Medistim ASA's average Cyclically Adjusted Revenue Growth Rate was 11.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Medistim ASA was 13.00% per year. The lowest was 7.90% per year. And the median was 11.10% per year.

As of today (2026-07-23), Medistim ASA's current stock price is €20.20. Medistim ASA's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €2.46. Medistim ASA's Cyclically Adjusted PS Ratio of today is 8.21.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medistim ASA was 23.03. The lowest was 4.75. And the median was 9.79.


Medistim ASA  (FRA:MD1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medistim ASA's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=20.20/2.46
=8.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medistim ASA was 23.03. The lowest was 4.75. And the median was 9.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Medistim ASA Cyclically Adjusted Revenue per Share Related Terms


Medistim ASA Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Medistim ASA's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medistim ASA Cyclically Adjusted Revenue per Share Chart

Medistim ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.85 1.88 2.04 2.05 2.28

Medistim ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.18 2.15 2.22 2.28 2.46

FRA:MD1 vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Medistim ASA's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medistim ASA Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medistim ASA's Cyclically Adjusted PS Ratio falls into.


FRA:MD1
99GF Score
Medistim ASA FRA:MD1
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medistim ASA Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medistim ASA's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.988/141.0300*141.0300
=0.988

Current CPI (Mar. 2026) = 141.0300.

Medistim ASA Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.397 103.800 0.539
201609 0.407 104.200 0.551
201612 0.379 104.400 0.512
201703 0.450 105.000 0.604
201706 0.401 105.800 0.535
201709 0.446 105.900 0.594
201712 0.430 106.100 0.572
201803 0.426 107.300 0.560
201806 0.443 108.500 0.576
201809 0.444 109.500 0.572
201812 0.529 109.800 0.679
201903 0.502 110.400 0.641
201906 0.529 110.600 0.675
201909 0.474 111.100 0.602
201912 0.487 111.300 0.617
202003 0.501 111.200 0.635
202006 0.422 112.100 0.531
202009 0.424 112.900 0.530
202012 0.452 112.900 0.565
202103 0.555 114.600 0.683
202106 0.593 115.300 0.725
202109 0.550 117.500 0.660
202112 0.557 118.900 0.661
202203 0.653 119.800 0.769
202206 0.624 122.600 0.718
202209 0.625 125.600 0.702
202212 0.711 125.900 0.796
202303 0.627 127.600 0.693
202306 0.642 130.400 0.694
202309 0.593 129.800 0.644
202312 0.644 131.900 0.689
202403 0.633 132.600 0.673
202406 0.692 133.800 0.729
202409 0.615 133.700 0.649
202412 0.702 134.800 0.734
202503 0.859 136.100 0.890
202506 0.799 137.800 0.818
202509 0.782 138.500 0.796
202512 0.843 139.100 0.855
202603 0.988 141.030 0.988

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €2.46 mean?
Medistim ASA (FRA:MD1) has a Cyclically Adjusted Revenue per Share of €2.46 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medistim ASA and its competitors.
Is Medistim ASA's Cyclically Adjusted Revenue per Share too high?
Medistim ASA's current Cyclically Adjusted Revenue per Share is €2.46. Overall, Medistim ASA has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Medistim ASA's Cyclically Adjusted Revenue per Share of €2.46 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medistim ASA and its competitors. Medistim ASA's current Cyclically Adjusted Revenue per Share is €2.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (FRA:MD1) is currently considered Modestly Undervalued. The stock's GF Value™ is €23.18, compared to a current price of €20.20 — trading 12.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €2.46. Medistim ASA's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Medistim ASA (FRA:MD1), the current Cyclically Adjusted Revenue per Share is €2.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medistim ASA (FRA:MD1) Overvalued in 2026?

Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued. The current stock price of €20.20 is trading 12.9% below its estimated GF Value™ of €23.18. GuruFocus considers Medistim ASA to be Modestly Undervalued.

Key valuation signals for FRA:MD1:

  • Cyclically Adjusted Revenue per Share: €2.46
  • GF Value™: €23.18 vs. price of €20.20 (12.9% below fair value)
  • GF Score™: 99/100 with 1 warning sign

No single metric tells the full story. See the FRA:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medistim ASA Business Description

Address Okernveien 94, Oslo, NOR, 0579
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
99GF Score

Get the complete analysis for FRA:MD1

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.20
Price
€23.18
GF Value